Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P. Fendler(Essen University Hospital), Rainer Hamacher(Technical University of Munich), Justin Ferdinandus(German Cancer Research Center), Pedro Fragoso Costa(Essen University Hospital), Sebastian Bauer(University of Duisburg-Essen), Martin Schüler(Essen University Hospital), Manuel Weber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christoph Rischpler(German Cancer Research Center), Marit Ahrens(Goethe University Frankfurt), Lale Umutlu(Essen University Hospital), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Katharina Lueckerath(German Cancer Research Center), Lukas Kessler(German Cancer Research Center), Maria Lippert(West German Heart and Vascular Center Essen), Jens T. Siveke(German Cancer Research Center), Ken Herrmann(Klinikum rechts der Isar), Ilektra A. Mavroeidi(German Cancer Research Center), Karina Kostbade(German Cancer Research Center)
Cited by 145
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k